Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information
Elite Pharmaceuticals (OTCQB:ELTP), a specialty pharmaceutical company focused on niche generic products, has reported strong financial results for fiscal year 2025. The company achieved consolidated revenues of $84.0 million, marking a significant 48% increase from the previous fiscal year. Operating profits reached $19.6 million, showing an impressive 81% growth year-over-year.
The substantial improvement in operating performance was primarily driven by the successful launch of Elite's lisdexamfetamine products during Fiscal 2025, along with robust growth in Elite label product lines that were introduced in the previous fiscal year. The company has scheduled a conference call for July 1, 2025, at 11:30 AM EDT to discuss these results and provide business updates.
Elite Pharmaceuticals (OTCQB:ELTP), un'azienda farmaceutica specializzata in prodotti generici di nicchia, ha riportato risultati finanziari solidi per l'anno fiscale 2025. La società ha raggiunto ricavi consolidati di 84,0 milioni di dollari, segnando un significativo incremento del 48% rispetto all'anno fiscale precedente. I profitti operativi hanno toccato i 19,6 milioni di dollari, mostrando una crescita impressionante dell'81% anno su anno.
Il miglioramento sostanziale nelle prestazioni operative è stato principalmente guidato dal lancio di successo dei prodotti lisdexamfetamina di Elite durante il 2025 fiscale, insieme a una robusta crescita delle linee di prodotti a marchio Elite introdotte nell'anno fiscale precedente. La società ha programmato una conference call per il 1° luglio 2025 alle 11:30 EDT per discutere questi risultati e fornire aggiornamenti sul business.
Elite Pharmaceuticals (OTCQB:ELTP), una empresa farmacéutica especializada en productos genéricos de nicho, ha reportado resultados financieros sólidos para el año fiscal 2025. La compañía alcanzó ingresos consolidados de 84.0 millones de dólares, lo que representa un significativo aumento del 48% respecto al año fiscal anterior. Las ganancias operativas llegaron a 19.6 millones de dólares, mostrando un impresionante crecimiento del 81% interanual.
La mejora sustancial en el desempeño operativo fue impulsada principalmente por el exitoso lanzamiento de los productos de lisdexanfetamina de Elite durante el año fiscal 2025, junto con un sólido crecimiento en las líneas de productos con etiqueta Elite introducidas en el año fiscal anterior. La empresa ha programado una llamada de conferencia para el 1 de julio de 2025 a las 11:30 AM EDT para discutir estos resultados y proporcionar actualizaciones comerciales.
Elite Pharmaceuticals (OTCQB:ELTP)는 틈새 제네릭 제품에 주력하는 전문 제약회사로서 2025 회계연도에 강력한 재무 실적을 보고했습니다. 회사는 8400만 달러의 통합 매출을 달성했으며, 이는 전년 대비 48%의 큰 증가를 나타냅니다. 영업 이익은 1960만 달러에 달해 전년 대비 81%의 인상적인 성장을 기록했습니다.
영업 실적의 상당한 개선은 주로 2025 회계연도 동안 Elite의 리스덱삼페타민 제품 성공적인 출시와 전 회계연도에 도입된 Elite 라벨 제품 라인의 강력한 성장에 힘입은 것입니다. 회사는 2025년 7월 1일 오전 11시 30분(동부 표준시)에 이번 실적과 사업 업데이트를 논의하기 위한 컨퍼런스 콜을 예정하고 있습니다.
Elite Pharmaceuticals (OTCQB:ELTP), une société pharmaceutique spécialisée dans les produits génériques de niche, a publié de solides résultats financiers pour l'exercice 2025. L'entreprise a réalisé un chiffre d'affaires consolidé de 84,0 millions de dollars, soit une augmentation significative de 48% par rapport à l'exercice précédent. Les bénéfices d'exploitation ont atteint 19,6 millions de dollars, affichant une croissance impressionnante de 81% d'une année sur l'autre.
Cette nette amélioration des performances opérationnelles a été principalement portée par le lancement réussi des produits de lisdexamfétamine d'Elite durant l'exercice 2025, ainsi que par une forte croissance des gammes de produits sous marque Elite introduites l'exercice précédent. La société a programmé une conférence téléphonique le 1er juillet 2025 à 11h30 EDT pour discuter de ces résultats et fournir des mises à jour commerciales.
Elite Pharmaceuticals (OTCQB:ELTP), ein auf Nischen-Generika spezialisiertes Pharmaunternehmen, hat für das Geschäftsjahr 2025 starke Finanzergebnisse gemeldet. Das Unternehmen erzielte konsolidierte Umsatzerlöse von 84,0 Millionen US-Dollar, was eine deutliche Steigerung von 48% gegenüber dem Vorjahr darstellt. Der Betriebsgewinn erreichte 19,6 Millionen US-Dollar und verzeichnete ein beeindruckendes Wachstum von 81% im Jahresvergleich.
Die deutliche Verbesserung der operativen Leistung wurde hauptsächlich durch die erfolgreiche Markteinführung der Lisdexamfetamin-Produkte von Elite im Geschäftsjahr 2025 sowie durch ein starkes Wachstum der Elite-eigenen Produktlinien, die im Vorjahr eingeführt wurden, angetrieben. Das Unternehmen hat eine Telefonkonferenz für den 1. Juli 2025 um 11:30 Uhr EDT angesetzt, um diese Ergebnisse zu besprechen und Geschäftsaktualisierungen zu geben.
- None.
- None.
Conference Call Scheduled for Tuesday, July 1 at 11:30 AM EDT
Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2025 ("Fiscal 2025").
Consolidated revenues for Fiscal 2025 were
Conference Call Information
Elite's management will host a conference call to discuss the year-end 2024 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
| Date: | July 1, 2025 |
| Time: | 11:30 AM EDT |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com Financial questions by 7:00 PM EDT on Monday, June 30, 2025 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
The financial statements can be viewed for Elite's Fiscal Year 2025 on Form 10-K here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationally under the Elite Laboratories, Inc. label. Elite also has products licensed to TAGI Pharma. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257239
FAQ
What were Elite Pharmaceuticals (ELTP) fiscal year 2025 revenue results?
How much did Elite Pharmaceuticals (ELTP) operating profits grow in fiscal 2025?
What drove Elite Pharmaceuticals (ELTP) growth in fiscal 2025?
When is Elite Pharmaceuticals (ELTP) fiscal 2025 earnings conference call?
